IssuerAnnouncementDetailsV2Portlet
Actions
Aldukheil Financial Group “Aldukheil” announces the final Price for the Initial Public Offering of Avalon Pharma
1058
Aldukheil
0.00
%
1445/07/12 24/01/2024 15:26:04
| Element List | Explanation |
|---|---|
| Announcement Detail | Aldukheil Financial Group “Aldukheil”, as Financial Advisor and Bookrunner for the Initial Public Offering of The Middle East Pharmaceutical Industries company “Avalon Pharma" (“the Company”) on the Main Market, announces that the book building process has been successfully concluded for the total of (6,000,000) ordinary shares representing (30%) of the Company’s shares (“the Offering”), and the Offering Price was determined at SAR 82 per share, with a coverage of 138.76 times of the total shares offered. The IPO subscription period for Individual Subscribers will commence on Tuesday 18-07-1445H (corresponding to 30-01-2024G) and end on Thursday 20-07-1445H (corresponding to 01-02-2024G), and a maximum number of (600,000) shares will be allocated to Individual Subscribers, representing 10% of the total Offer Shares. For additional information, kindly refer to the prospectus available on the following websites: the website of the Company (www. avalonpharmaceutical.com) the website of the Financial Advisor & Bookrunner (www.aldukheil.com.sa) the website of the Capital Market Authority “CMA” (www.cma.org.sa) Kindly refer to the attached file for additional information. |
| Attached Documents |  |
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.
Share
Company Performance
Add To Watchlist
In your Watchlist
Add To Watchlist
LoginPortletPopupv2
Actions
AddtoWatchlistv2
Actions